Metabolic reprogramming and AMPKα1 pathway activation by caulerpin in colorectal cancer cells

International Journal of Oncology

Volumn 50, Issue 1, 2017, Pages 161-172

  Yu, Hua ^a   Zhang, Huiqin ^a   Dong, Mingjun ^a   Wu, Zhou ^a   Shen, Zhonglei ^a   Xie, Yangyang ^a   Kong, Zhenfang ^a   Dai, Xiaoyu ^a   Xu, Binbin ^a  

^a Ningbo No2 Hospital   (China)

Author keywords

AMPK; Caulerpin; Colorectal cancer; Glycolysis; MTORC1; OXPHOS

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CAULERPIN; GLUCOSE; GLUCOSE TRANSPORTER 1; HEXOKINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN AMPKALPHA1; PROTEIN HKII; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG; INDOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PRKAA1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG STRUCTURE; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRUCTURE ANALYSIS; UPREGULATION; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MITOCHONDRION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR REPROGRAMMING; COLORECTAL NEOPLASMS; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; INDOLES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MITOCHONDRIA; MULTIPROTEIN COMPLEXES; OXIDATIVE PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85007578604     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3794     Document Type: Article

References (48)

1. Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin 64: 104-117, 2014.
2. Warburg O, Wind F and Negelein E: The metabolism of tumors in the body. J Gen Physiol 8: 519-530, 1927.
3. Ward PS and Thompson CB: Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. Cancer Cell 21: 297-308, 2012.
4. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM, Budigner GS, et al: Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3: e02242, 2014.
5. Inoki K, Kim J and Guan KL: AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 52: 381-400, 2012.
6. Sinha RA, Singh BK, Zhou J, Wu Y, Farah BL, Ohba K, Lesmana R, Gooding J, Bay BH and Yen PM: Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling. Autophagy 11: 1341-1357, 2015.
7. Wu XB, Liu Y, Wang GH, Xu X, Cai Y, Wang HY, Li YQ, Meng HF, Dai F and Jin JD: Mesenchymal stem cells promote colorectal cancer progression through AMPK/mTOR-mediated NF-κB activation. Sci Rep 6: 21420, 2016.
8. Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, Gao FH, Xu MH, Chen GQ, Han ZG and Fang JY: mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol 16: 2617-2628, 2009.
9. He X, Lin X, Cai M, Zheng X, Lian L, Fan D, Wu X, Lan P and Wang J: Overexpression of Hexokinase 1 as a poor prognosticator in human colorectal cancer. Tumour Biol 37: 3887-3895, 2016.
10. Hamabe A, Yamamoto H, Konno M, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Nishida N, Kawamoto K, et al: Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1α in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis. Cancer Sci 105: 1100-1108, 2014.
11. Gandham SK, Talekar M, Singh A and Amiji MM: Inhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis. Int J Nanomedicine 10: 4405-4423, 2015.
12. Xintaropoulou C, Ward C, Wise A, Marston H, Turnbull A and Langdon SP: A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models. Oncotarget 6: 25677-25695, 2015.
13. Liu Y, Morgan JB, Coothankandaswamy V, Liu R, Jekabsons MB, Mahdi F, Nagle DG and Zhou YD: The Caulerpa pigment caulerpin inhibits HIF-1 activation and mitochondrial respiration. J Nat Prod 72: 2104-2109, 2009.
14. Ferramosca A, Conte A, Guerra F, Felline S, Rimoli MG, Mollo E, Zara V and Terlizzi A: Metabolites from invasive pests inhibit mitochondrial complex II: A potential strategy for the treatment of human ovarian carcinoma? Biochem Biophys Res Commun 473: 1133-1138, 2016.
15. Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, Teitell MA, Wu H, Ribas A, Lo RS, et al: Glucose deprivation activates a metabolic and signaling amplifcation loop leading to cell death. Mol Syst Biol 8: 589, 2012.
16. Priebe A, Tan L, Wahl H, Kueck A, He G, Kwok R, Opipari A and Liu JR: Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells. Gynecol Oncol 122: 389-395, 2011.
17. Chen Y, Qing W, Sun M, Lv L, Guo D and Jiang Y: Melatonin protects hepatocytes against bile acid-induced mitochondrial oxidative stress via the AMPK-SIRT3-SOD2 pathway. Free Radic Res 49: 1275-1284, 2015.
18. Wang SY, Wei YH, Shieh DB, Lin LL, Cheng SP, Wang PW and Chuang JH: 2-Deoxy-d-Glucose can complement doxorubicin and sorafenib to suppress the growth of papillary thyroid carcinoma cells. PLoS One 10: e0130959, 2015.
19. Wei L, Zhou Y, Dai Q, Qiao C, Zhao L, Hui H, Lu N and Guo QL: Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis 4: e601, 2013.
20. Jeong SM, Lee J, Finley LW, Schmidt PJ, Fleming MD and Haigis MC: SIRT3 regulates cellular iron metabolism and cancer growth by repressing iron regulatory protein 1. Oncogene 34: 2115-2124, 2015.
21. Song J, Feng L, Zhong R, Xia Z, Zhang L, Cui L, Yan H, Jia X and Zhang Z: Icariside II inhibits the EMT of NSCLC cells in inflammatory microenvironment via down-regulation of Akt/NF-κB signaling pathway. Mol Carcinog: Feb 9, 2016 (Epub ahead of print).
22. Liu Y, Veena CK, Morgan JB, Mohammed KA, Jekabsons MB, Nagle DG and Zhou YD: Methylalpinum isoflavone inhibits hypoxia-inducible factor-1 (HIF-1) activation by simultaneously targeting multiple pathways. J Biol Chem 284: 5859-5868, 2009.
23. Bonifati S, Daly MB, St Gelais C, Kim SH, Hollenbaugh JA, Shepard C, Kennedy EM, Kim DH, Schinazi RF, Kim B, et al: SAMHD1 controls cell cycle status, Apoptosis and HIV-1 infection in monocytic THP-1 cells. Virology 495: 92-100, 2016.
24. Zhou X, Chen M, Zeng X, Yang J, Deng H, Yi L and Mi MT: Resveratrol regulates mitochondrial reactive oxygen species homeostasis through Sirt3 signaling pathway in human vascular endothelial cells. Cell Death Dis 5: e1576, 2014.
25. Zhang W, Tong D, Liu F, Li D, Li J, Cheng X and Wang Z: RPS7 inhibits colorectal cancer growth via decreasing HIF-1α-mediated glycolysis. Oncotarget 7: 5800-5814, 2016.
26. Yamada C, Aikawa T, Okuno E, Miyagawa K, Amano K, Takahata S, Kimata M, Okura M, Iida S and Kogo M: TGF-β in jaw tumor fuids induces RANKL expression in stromal fbro-blasts. Int J Oncol 49: 499-508, 2016.
27. Zhang M, Dong Y, Xu J, Xie Z, Wu Y, Song P, Guzman M, Wu J and Zou MH: Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide. Circ Res 102: 328-337, 2008.
28. Hardie DG, Ross FA and Hawley SA: AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13: 251-262, 2012.
29. Luczak ED and Anderson ME: CaMKII oxidative activation and the pathogenesis of cardiac disease. J Mol Cell Cardiol 73: 112-116, 2014.
30. Dang CV: Links between metabolism and cancer. Genes Dev 26: 877-890, 2012.
31. Hensley CT, Wasti AT and DeBerardinis RJ: Glutamine and cancer: Cell biology, Physiology, And clinical opportunities. J Clin Invest 123: 3678-3684, 2013.
32. Willems PH, Rossignol R, Dieteren CE, Murphy MP and Koopman WJ: Redox homeostasis and mitochondrial dynamics. Cell Metab 22: 207-218, 2015.
33. Murphy MP: How mitochondria produce reactive oxygen species. Biochem J 417: 1-13, 2009.
34. Pollak M: Overcoming drug development bottlenecks with repur-posing: Repurposing biguanides to target energy metabolism for cancer treatment. Nat Med 20: 591-593, 2014.
35. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, Wang T, Chen WW, Clish CB and Sabatini DM: Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508: 108-112, 2014.
36. Duarte F V, Amorim JA, Palmeira CM and Rolo AP: Regulation of mitochondrial function and its impact in metabolic stress. Curr Med Chem 22: 2468-2479, 2015.
37. Shackelford DB and Shaw RJ: The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575, 2009.
38. Fennema E, Rivron N, Rouwkema J, Van Blitterswijk C and de Boer J: Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol 31: 108-115, 2013.
39. Lu PH, Chen MB, Ji C, Li WT, Wei MX and Wu MH: Aqueous Oldenlandia diffusa extracts inhibits colorectal cancer cells via activating AMP-activated protein kinase signalings. Oncotarget: Jun 13, 2016 (Epub ahead of print).
40. Inoki K, Zhu T and Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590, 2003.
41. Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, Castrillon DH, Kabbani W and Brugarolas J: Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia. Mol Cell Biol 31: 1870-1884, 2011.
42. Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, et al: Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39: 171-183, 2010.
43. Fanciulli M, Bruno T, Giovannelli A, Gentile FP, Di Padova M, Rubiu O and Floridi A: Energy metabolism of human LoVo colon carcinoma cells: Correlation to drug resistance and infuence of lonidamine. Clin Cancer Res 6: 1590-1597, 2000.
44. Bentz S, Cee A, Endlicher E, Wojtal KA, Naami A, Pesch T, Lang S, Schubert P, Fried M, Weber A, et al: Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. Digestion 88: 182-192, 2013.
45. Qin Y, Cheng C, Lu H and Wang Y: miR-4458 suppresses glycolysis and lactate production by directly targeting hexokinase2 in colon cancer cells. Biochem Biophys Res Commun 469: 37-43, 2016.
46. Fath MA, Diers AR, Aykin-Burns N, Simons AL, Hua L and Spitz DR: Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells. Cancer Biol Ther 8: 1228-1236, 2009.
47. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, et al: A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 71: 523-530, 2013.
48. Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ and Pedersen PL: A translational study 'case report' on the small molecule 'energy blocker' 3-bromopyruvate (3BP) as a potent anticancer agent: From bench side to bedside. J Bioenerg Biomembr 44: 163-170, 2012.